Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection
The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
eLife Sciences Publications Ltd
2021-04-01
|
| Series: | eLife |
| Subjects: | |
| Online Access: | https://elifesciences.org/articles/68808 |
| _version_ | 1828221548444516352 |
|---|---|
| author | Nick K Jones Lucy Rivett Shaun Seaman Richard J Samworth Ben Warne Chris Workman Mark Ferris Jo Wright Natalie Quinnell Ashley Shaw Cambridge COVID-19 Collaboration Ian G Goodfellow Paul J Lehner Rob Howes Giles Wright Nicholas J Matheson Michael P Weekes |
| author_facet | Nick K Jones Lucy Rivett Shaun Seaman Richard J Samworth Ben Warne Chris Workman Mark Ferris Jo Wright Natalie Quinnell Ashley Shaw Cambridge COVID-19 Collaboration Ian G Goodfellow Paul J Lehner Rob Howes Giles Wright Nicholas J Matheson Michael P Weekes |
| author_sort | Nick K Jones |
| collection | DOAJ |
| description | The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease. |
| first_indexed | 2024-04-12T16:42:47Z |
| format | Article |
| id | doaj.art-f18c801589924864962d116dea1c1740 |
| institution | Directory Open Access Journal |
| issn | 2050-084X |
| language | English |
| last_indexed | 2024-04-12T16:42:47Z |
| publishDate | 2021-04-01 |
| publisher | eLife Sciences Publications Ltd |
| record_format | Article |
| series | eLife |
| spelling | doaj.art-f18c801589924864962d116dea1c17402022-12-22T03:24:43ZengeLife Sciences Publications LtdeLife2050-084X2021-04-011010.7554/eLife.68808Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infectionNick K Jones0https://orcid.org/0000-0003-4475-7761Lucy Rivett1https://orcid.org/0000-0002-2781-9345Shaun Seaman2Richard J Samworth3Ben Warne4Chris Workman5Mark Ferris6Jo Wright7Natalie Quinnell8Ashley Shaw9Cambridge COVID-19 Collaboration10Ian G Goodfellow11https://orcid.org/0000-0002-9483-510XPaul J Lehner12https://orcid.org/0000-0001-9383-1054Rob Howes13Giles Wright14Nicholas J Matheson15https://orcid.org/0000-0002-3318-1851Michael P Weekes16https://orcid.org/0000-0003-3196-5545Cambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United KingdomCambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, United KingdomMedical Research Council Biostatistics Unit, University of Cambridge, Cambridge, United KingdomStatistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, Cambridge, United KingdomCambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United KingdomOccupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United KingdomOccupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United KingdomOccupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United KingdomOccupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United KingdomCambridge University NHS Hospitals Foundation Trust, Cambridge, United KingdomCambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United KingdomDivision of Virology, Department of Pathology, University of Cambridge, Cambridge, United KingdomCambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United KingdomCambridge COVID-19 Testing Centre and AstraZeneca, Anne McLaren Building, Cambridge, United KingdomOccupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, United KingdomCambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease, University of Cambridge, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; NHS Blood and Transplant, Cambridge, United KingdomCambridge University NHS Hospitals Foundation Trust, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute for Medical Research, University of Cambridge, Cambridge, United KingdomThe BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of asymptomatic SARS-CoV-2 infection remains unknown. We previously demonstrated frequent pauci- and asymptomatic SARS-CoV-2 infection amongst healthcare workers (HCWs) during the UK’s first wave of the COVID-19 pandemic, using a comprehensive PCR-based HCW screening programme (Rivett et al., 2020; Jones et al., 2020). Here, we evaluate the effect of first-dose BNT162b2 vaccination on test positivity rates and find a fourfold reduction in asymptomatic infection amongst HCWs ≥12 days post-vaccination. These data provide real-world evidence of short-term protection against asymptomatic SARS-CoV-2 infection following a single dose of BNT162b2 vaccine, suggesting that mass first-dose vaccination will reduce SARS-CoV-2 transmission, as well as the burden of COVID-19 disease.https://elifesciences.org/articles/68808SARS-CoV-2COVID-19BNT162b2vaccinationasymptomaticPfizer-BioNTech |
| spellingShingle | Nick K Jones Lucy Rivett Shaun Seaman Richard J Samworth Ben Warne Chris Workman Mark Ferris Jo Wright Natalie Quinnell Ashley Shaw Cambridge COVID-19 Collaboration Ian G Goodfellow Paul J Lehner Rob Howes Giles Wright Nicholas J Matheson Michael P Weekes Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection eLife SARS-CoV-2 COVID-19 BNT162b2 vaccination asymptomatic Pfizer-BioNTech |
| title | Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection |
| title_full | Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection |
| title_fullStr | Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection |
| title_full_unstemmed | Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection |
| title_short | Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection |
| title_sort | single dose bnt162b2 vaccine protects against asymptomatic sars cov 2 infection |
| topic | SARS-CoV-2 COVID-19 BNT162b2 vaccination asymptomatic Pfizer-BioNTech |
| url | https://elifesciences.org/articles/68808 |
| work_keys_str_mv | AT nickkjones singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT lucyrivett singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT shaunseaman singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT richardjsamworth singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT benwarne singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT chrisworkman singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT markferris singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT jowright singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT nataliequinnell singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT ashleyshaw singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT cambridgecovid19collaboration singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT ianggoodfellow singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT pauljlehner singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT robhowes singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT gileswright singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT nicholasjmatheson singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection AT michaelpweekes singledosebnt162b2vaccineprotectsagainstasymptomaticsarscov2infection |